ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…
Biotechnology
US, Waltham [HQ]
Ratios
14 Sheets · Starting from 2022Margins, Growth Rates In %
| Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||
| Gross Margin | 100.00 | 100.00 | 100.00 | -145.03 | -78.57 | -30.66 | -144.85 | -190.60 | -21.04 | -223.11 | -39.20 | 13.38 | 99.84 | 99.84 | |
| Profit Margin | -365.14 | -301.86 | -448.24 | -204.90 | -119.15 | -71.01 | -239.42 | -322.31 | -83.17 | -311.94 | -148.40 | -50.40 | -204.93 | -204.93 | |
| Operating Margin | -367.46 | -311.77 | -447.86 | -205.46 | -119.43 | -63.66 | -206.37 | -269.83 | -51.09 | -298.20 | -112.04 | -102.41 | -203.06 | -203.06 | |
|
EPS Growth
|
-38.10 | 2.30 | -11.77 | 8.42 | 4.60 | 14.46 | -132.39 | -9.09 | 45.56 | -22.45 | 31.67 | 53.66 | -131.58 | - - | |
| EPS USD | -87.00 | -85.00 | -95.00 | -87.00 | -83.00 | -71.00 | -165.00 | -180.00 | -98.00 | -120.00 | -82.00 | -38.00 | -88.00 | -88.00 | |
| Return on Assets (ROA) | -37.11 | -26.78 | -40.66 | -34.09 | -43.17 | -19.35 | -50.04 | -78.81 | -32.58 | -56.76 | -51.81 | -18.78 | -63.89 | -63.89 | |
| Return on Equity (ROE) | -49.89 | -41.63 | -87.40 | -59.76 | -94.27 | -173.03 | 177.04 | 102.54 | 536.53 | -1,405.74 | 160.39 | -74.45 | -143.06 | -143.06 | |
| Return on Invested Capital (ROIC) | -49.95 | -41.59 | -87.40 | -59.76 | -94.27 | -110.18 | -362.21 | 234.79 | 334.86 | -6,344.09 | 441.01 | -150.54 | -119.21 | -119.21 | |
| Solvency | |||||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | - - | - - | - - | - - | 6.19 | 41.82 | 48.76 | -2.21 | -3.15 | 11.39 | 6.73 | 4.37 | 4.37 | |
| Debt/Equity | - - | - - | - - | - - | - - | 55.36 | -147.95 | -63.44 | 36.39 | -77.89 | -35.27 | 26.67 | 9.78 | 9.78 | |
| Debt/EBITDA | 212.81 | 307.89 | 219.88 | 267.04 | 198.88 | 502.88 | 117.41 | 127.77 | 476.76 | 169.55 | 227.27 | 1,371.57 | 119.47 | 119.47 | |
|
Debt/Capitalization
|
- - | - - | - - | - - | - - | 35.63 | 308.56 | -173.51 | 26.68 | -352.18 | -54.49 | 21.06 | 8.91 | 8.91 | |
| Long-Term Debt/Capitalization | - - | - - | - - | - - | - - | - - | 530.28 | -173.51 | -12.94 | 14.74 | -45.70 | 17.23 | 6.68 | 6.68 | |
| Interest Debt per Share USD | - - | -0.03 | - - | - - | - - | 0.29 | 1.61 | 1.11 | 0.10 | 0.01 | 0.30 | 0.27 | 0.08 | 0.08 | |
| Debt Growth | - - | - - | - - | - - | - - | - - | - - | -100.00 | - - | 0.68 | 1,200.73 | -11.01 | -36.19 | - - | |
| Liquidity | |||||||||||||||
| Current Ratio | 847.33 | 1,312.69 | 1,109.31 | 1,016.85 | 669.34 | 776.62 | 406.50 | 316.17 | 478.94 | 374.32 | 227.65 | 240.23 | 225.79 | 225.79 | |
| Quick Ratio | 822.51 | 1,344.73 | 998.30 | 1,027.91 | 684.51 | 792.83 | 410.30 | 302.58 | 488.32 | 391.55 | 262.85 | 258.62 | 240.54 | 240.54 | |
| Cash Ratio | 789.73 | 1,312.69 | 990.14 | 1,016.85 | 669.34 | 776.62 | 406.50 | 286.80 | 478.94 | 374.32 | 227.65 | 240.23 | 225.79 | 225.79 | |
| Operating Cash Flow Ratio | -200 | - - | -200 | -300 | -200 | -100 | -200 | -200 | - - | -200 | -100 | - - | -100 | -100 | |
| Turnover | |||||||||||||||
| Inventory Turnover | - - | - - | - - | 12,385.92 | 3,625.70 | 3,808.11 | 16,197.91 | 6,446.72 | 13,462.33 | -1,052.01 | -350.51 | -376.97 | 1.09 | -0.61 | |
| Receivables Turnover | 411.30 | 413.56 | 1,234.49 | 1,675.39 | 1,857.24 | 1,474.34 | 2,617.89 | 552.34 | 2,207.82 | 445.98 | 301.93 | 588.07 | 605.08 | 605.08 | |
| Payables Turnover | - - | - - | - - | 1,935.82 | 2,219.51 | 1,373.41 | 1,276.41 | 1,789.89 | 1,632.08 | 1,530.01 | 1,152.95 | 1,201.43 | 0.39 | 0.39 | |
|
Asset Turnover
|
10.16 | 8.87 | 9.07 | 16.64 | 36.23 | 27.26 | 20.90 | 24.45 | 39.18 | 18.20 | 34.91 | 37.26 | 31.18 | 31.18 | |
| Fixed Turnover | 85.40 | 143.97 | 140.61 | 329.55 | 417.42 | 526.28 | 264.28 | 249.40 | 794.11 | 417.47 | 364.35 | 667.10 | 744.67 | 744.67 | |
| Coverage | |||||||||||||||
| Interest Coverage | 88,336.21 | 3,144.62 | -118,156.45 | 36,873.23 | 42,832.93 | -1,001.75 | -615.15 | - - | -352.72 | -1,496.17 | -543.02 | -583.94 | -5,303.55 | -5,303.55 | |
| Asset Coverage | - - | - - | - - | - - | - - | - - | 200 | - - | 11,200 | 10,300 | 600 | 900 | 1,500 | 1,500 | |
| Cash Flow Coverage (CFGR) | - - | - - | - - | - - | - - | -284.52 | -103.69 | -147.11 | -117.40 | 1,789.29 | -329.15 | -329.09 | -1,507.49 | -1,507.49 | |
| EBITDA Coverage | 88,400 | 3,200 | -118,000 | 36,800 | 42,800 | -1,000 | -600 | - - | -300 | -1,400 | -300 | - - | -5,200 | -5,200 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | -200 | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -9.33 | -6.94 | -5.70 | -5.04 | -7.05 | -4.91 | -53.63 | -88.23 | -15.27 | -24.99 | -16.11 | -5.87 | -11.85 | -17.72 | |
|
Price/Earnings (P/E)
|
-1,071.44 | -1,441.68 | -1,753.80 | -1,984.65 | -1,419.41 | -2,036.96 | -186.48 | -113.34 | -654.73 | -400.15 | -620.73 | -1,703.86 | -844.19 | -564.31 | |
| Price/Earnings Growth (PEG) | -28.13 | 627.13 | -149.07 | 235.68 | 308.72 | 140.89 | -1.41 | -12.47 | 14.37 | -17.82 | 19.60 | 31.75 | -6.42 | - - | |
|
Price/Book (P/B)
|
534.55 | 600.22 | 1,532.80 | 1,185.95 | 1,338.13 | 3,524.46 | -330.14 | -116.21 | -3,512.80 | 5,625.03 | -995.61 | 1,268.49 | 1,207.72 | 807.32 | |
| Price/Tangible Book (P/TB) | 534.55 | 600.22 | 1,532.80 | 1,185.95 | 1,338.13 | 3,524.46 | -330.14 | -116.21 | -3,512.80 | 5,625.03 | -995.61 | 1,268.49 | 1,207.72 | 807.32 | |
| Price/Sales (P/S) | 3,912.31 | 4,351.84 | 7,861.26 | 4,066.53 | 1,691.18 | 1,446.35 | 446.46 | 365.29 | 544.51 | 1,248.22 | 921.19 | 858.80 | 1,730.01 | 1,156.45 | |
|
Price/Cash Flow (P/CF)
|
-1,344.11 | -10,515.99 | -3,750.19 | -2,396.46 | -1,888.07 | -2,237.66 | -215.21 | -124.53 | 8,222.58 | -403.64 | -857.64 | -1,445.16 | -818.94 | -547.43 | |
| Price/Free CF (P/FCF) | -1,295.15 | -8,386.13 | -3,457.00 | -2,255.45 | -1,638.18 | -1,972.74 | -198.65 | -118.98 | 9,628.06 | -391.30 | -830.89 | -1,428.50 | -814.11 | -544.20 | |
| Price/Operating CF (P/OCF) | -1,344.11 | -10,515.99 | -3,750.19 | -2,396.46 | -1,888.07 | -2,237.66 | -215.21 | -124.53 | 8,222.58 | -403.64 | -857.64 | -1,445.16 | -818.94 | -547.43 |